Location Directory

Clinical trials in Cincinnati, Ohio

This page shows live ClinicalTrials.gov search results for Cincinnati, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10556

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
Interventions: Benralizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Aurora, Colorado • Cincinnati, Ohio • Highland Hills, Ohio

Conditions: Recurrent Pericarditis, Heart Diseases, Pericarditis
Interventions: KPL-387; Drug
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 21
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 17 more

Conditions: Bronchiectasis
Interventions: BI 1291583, Placebo matching BI 1291583; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years and older
Enrollment: 1,755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Generalized Myasthenia Gravis
Interventions: Pozelimab + Cemdisiran, Cemdisiran, Placebo, Pozelimab; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 19
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 16 more

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Vedolizumab IV, Vedolizumab SC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more

Conditions: Immunization; Infection, Transplantation Infection, Influenza
Interventions: Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 17 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Stanford, California • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Desmoplastic Small Round Cell Tumor, Osteosarcoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Kidney Wilms Tumor, Recurrent Osteosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Wilms Tumor, Wilms Tumor
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Trastuzumab Deruxtecan; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 39 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 27 more

Conditions: Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Interventions: ASP2020; Drug
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 6 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Phoenix, Arizona • Southaven, Mississippi • Cincinnati, Ohio + 1 more

Conditions: Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Interventions: KPL-387, Placebo; Drug
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 33
States / cities: Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 27 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Claseprubart, Placebo; Drug
Lead sponsor: Dianthus Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 26 more

Conditions: Asthma
Interventions: Benralizumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Torrance, California • Ocala, Florida • Owensboro, Kentucky + 8 more

Conditions: Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors, Epidemiology, Chronic Kidney Disease(CKD), Hypertension
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 0 Minutes to 2 Weeks
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 48 more

Clinical trials in Cincinnati, Ohio

Filter and sort this location

Live official records

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

Transition to KPL-387 Monotherapy Dosing & Administration Study

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0